Healthy CD8+ T Cells

About Healthy CD8+ T Cells

Healthy Donor CD8+ T Cells

High-Purity Human CD8+ T Cells for Immunology and Cell Therapy Research

Human CD8+ T Cells are purified from peripheral blood of healthy adult donors under IRB-approved protocols. These CD8 positive cytotoxic T lymphocytes are essential mediators of cellular immunity, enabling antigen-specific killing of infected or malignant cells through perforin- and granzyme-mediated cytotoxic pathways. Healthy donor CD8+ T cells support applications in cancer immunotherapy research, infectious disease studies, immune activation assays, and T cell–based therapeutic development. Available cryopreserved, these cells deliver high viability and consistent functional performance for in vitro and in vivo studies.

Product Features

  • Research Use Only (RUO), CD8 positive T cells
  • Isolated from healthy, clinically screened donors
  • High purity and viability (≥90% CD8+ cells)
  • Cryopreserved in CryoStor® CS10 media
  • Processed within 24 hours of collection
  • IRB-approved protocols with electronic informed consent

Donor Metadata

  • Comprehensive donor screening and verified health status
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Self-reported medication, allergy, and infectious disease history

Applications

  • Cytotoxic T cell activation assays
  • Cancer immunotherapy and CAR-T research
  • Antigen-specific killing assays
  • Viral immunity studies
  • Single-cell and transcriptomic analysis

Compliance and Quality Assurance

  • IRB-approved collections and standardized procedures
  • 21 CFR Part 11–compliant e-consent system
  • HIPAA-compliant data management

Ordering & Customization

Human CD8+ T Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability.

Donor Metadata

  • Verified diagnosis and clinical history
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Medication and treatment background when available

Compliance and Quality Assurance

  • IRB-approved collections and standardized procedures
  • 21 CFR Part 11-compliant e-consent system
  • HIPAA-compliant data management

Ordering & Customization

Human CD8+ T Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.

Where can I find your complete catalog?
How long can samples be stored?

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

What customization options are available?

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Do you offer prospective collections?

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

What is the turnaround time for custom collections?

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

Do you have samples in stock?

YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

What does unique donor mean?

Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

Are samples collected under IRB-approved protocols?

YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

Frequently Asked Questions

×

Ask a Question

Need a custom CD8+ T Cells cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information